BlueLinx - BXC Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BlueLinx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BXC shares.
View BXC analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month target prices for BlueLinx's shares. Their BXC share price forecasts range from $115.00 to $127.00. On average, they predict the company's stock price to reach $121.00 in the next year. This suggests a possible upside of 43.6% from the stock's current price.
View analysts price targets for BXC or view top-rated stocks among Wall Street analysts.

BlueLinx's stock was trading at $71.11 at the beginning of 2023. Since then, BXC stock has increased by 18.5% and is now trading at $84.27.
View the best growth stocks for 2023 here.

BlueLinx saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 502,500 shares, an increase of 25.3% from the December 15th total of 401,000 shares. Based on an average trading volume of 83,900 shares, the short-interest ratio is presently 6.0 days. Approximately 5.7% of the shares of the stock are short sold.
View BlueLinx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our BXC earnings forecast.

BlueLinx Holdings Inc. (NYSE:BXC) announced its earnings results on Tuesday, November, 1st. The construction company reported $6.38 earnings per share for the quarter, topping the consensus estimate of $5.40 by $0.98. The construction company earned $1.06 billion during the quarter, compared to the consensus estimate of $1.07 billion. BlueLinx had a trailing twelve-month return on equity of 70.64% and a net margin of 7.38%.

56 employees have rated BlueLinx Chief Executive Officer Mitch Lewis on Glassdoor.com. Mitch Lewis has an approval rating of 49% among the company's employees. This puts Mitch Lewis in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other BlueLinx investors own include Novavax (NVAX), Micron Technology (MU), Co-Diagnostics (CODX), Livongo Health (LVGO), Intel (INTC), Maxar Technologies (MAXR), Civeo (CVEO), Nautilus (NLS), Sorrento Therapeutics (SRNE) and Hologic (HOLX).

BlueLinx trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXC."

BlueLinx's stock is owned by a number of institutional and retail investors. Top institutional investors include Hennessy Advisors Inc. (0.42%), SummerHaven Investment Management LLC (0.12%), Strs Ohio (0.10%), Exchange Traded Concepts LLC (0.06%), Allspring Global Investments Holdings LLC (0.04%) and BTC Capital Management Inc. (0.04%). Insiders that own company stock include Brian J Sasadu, Carol B Yancey, Kelly Janzen, Kim S Fennebresque, Mitchell B Lewis, Mitchell B Lewis, Nokomis Capital, LLC and Shyam K Reddy.
View institutional ownership trends.

Shares of BXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BXC stock can currently be purchased for approximately $84.27.

BlueLinx (NYSE:BXC) has a market capitalization of $761.80 million and generates $4.28 billion in revenue each year. The construction company earns $296.13 million in net income (profit) each year or $34.35 on an earnings per share basis.

The company employs 2,055 workers across the globe.

BlueLinx's mailing address is 1950 SPECTRUM CIRCLE SUITE 300, MARIETTA GA, 30067. The official website for the company is www.bluelinxco.com. The construction company can be reached via phone at (770) 953-7000, via email at ir@audentestx.com, or via fax at 770-221-8902.